Finetech Laboratories Ltd.

Svc Pharma LP

Purdue Pharma L.p.

Teva Pharmaceutical Industries Limited

Fine Tech Corporation

Par Pharmaceutical, Inc.

Finetech Pharmaceutical Ltd

Euro-celtique S.a.

Boris Tishin

Arie L Gutman

Gennady Nisnevich

Boris Pertsikov

Marina Etinger

Igor Rukhman

Irina Fedotev

Ram Khanolkar

Igor Zaltzman

Genady Nisnevich

Lev Yudovich

Eleonora Shkolnik

Michael Yuzefovich

Dina Blasberger

Judith Aronhime

Ben-Zion Dolitzky

Shlomit Wizel

Valerie Niddam-Hildesheim

Ben Zion Dolitzky

Gennadiy Nisnevich

Alex Vilenski

Albay Agazade

Boris Pertzikov

Igor Ruchman

Alex Vilensky

Alexander Vilensky

Gennady A Nisnevich

Gennady A Nisnevish

Boris M Pertsikov

Marina M Etinger

Irina M Fedotev

Methods for making trans-(&#x2212;)-&#x394;-tetrahydrocannabinol and trans-(+)-&#x394;-tetrahydrocannabinol are disclosed herein. In one embodiment, a trans-(&#x2212;)-&#x394;-tetrahydrocannabinol composition is prepared by allowing a composition comprising (&#xb1;)-&#x394;-tetrahydrocannabinol to separate on a chiral stationary phase to provide a trans-(&#x2212;)-&#x394;-tetrahydrocannabinol composition comprising at least about 99% by weight of trans-(&#x2212;)-&#x394;-tetrahydrocannabinol based on the total amount of trans-(&#x2212;)-&#x394;-tetrahydrocannabinol and trans-(+)-&#x394;-tetrahydrocannabinol. The invention also relates to methods for treating or preventing a condition such as pain comprising administering to a patient in need thereof an effective amount of a trans-(&#x2212;)-&#x394;-tetrahydrocannabinol having a purity of at least about 98% based on the total weight of cannabinoids.

[object Object]

Methods for making trans-(&#x2212;)-&#x394;-tetrahydrocannabinoI and trans-(+)-&#x394;-tetrahydrocannabinol are disclosed herein. In one embodiment, a trans-(&#x2212;)-&#x394;-tetrahydrocannabinoI composition is prepared by allowing a composition comprising (&#xb1;)-&#x394;-tetrahydrocannabinol to separate on a chiral stationary phase to provide a trans-(&#x2212;)-&#x394;-tetrahydrocannabinoI composition comprising at least about 99% by weight of trans-(&#x2212;)-&#x394;-tetrahydrocannabinol based on the total amount of trans-(&#x2212;)-&#x394;-tetrahydrocannabinol and trans-(+)-&#x394;-tetrahydrocannabinol. The invention also relates to methods for treating or preventing a condition such as pain comprising administering to a patient in need thereof an effective amount of a trans-(&#x2212;)-&#x394;-tetrahydrocannabinoI having a purity of at least about 98% based on the total weight of cannabinoids.

Methods for making trans-(&#x2212;)-&#x394;-tetrahydrocannabinol and trans-(+)-&#x394;-tetrahydrocannabinol are disclosed herein. In one embodiment, a trans-(&#x2212;)-&#x394;-tetrahydrocannabinol composition is prepared by allowing a composition comprising (&#xb1;)-&#x394;)-tetrahydrocannabinol to separate on a chiral stationary phase to provide a trans-(&#x2212;)-&#x394;-tetrahydrocannabinol composition comprising at least about 99% by weight of trans-(&#x2212;)-&#x394;-tetrahydrocannabinol based on the total amount of trans-(&#x2212;)-&#x394;-tetrahydrocannabinol and trans-(+)-&#x394;-tetrahydrocannabinol. The invention also relates to methods for treating or preventing a condition such as pain comprising administering to a patient in need thereof an effective amount of a trans-(&#x2212;)-&#x394;-tetrahydrocannabinol having a purity of at least about 98% based on the total weight of cannabinoids.

The invention provides a novel polymorphic form I of crystalline bimatoprost, method for preparation thereof and new crystalline intermediates in the preparation. This form I of crystalline bimatoprost is used in purification of crude bimatoprost and in storage of bimatoprost as active pharmaceutical intermediate. Use of the physical form of bimatoprost in the manufacture of a medicament is also disclosed.

Bimatoprost crystalline form I

The invention provides a novel process for the preparation of prostaglandins and analogues thereof, and new crystalline intermediates in the process.

Process for the preparation of prostaglandin derivatives

The invention provides methods for preparing amorphous physical form of cabergoline, and solvate form A of cabergoline useful in the preparation of the first mentioned physical form. A method for treating a prolactin disorder with medicaments prepared from amorphous physical form of cabergoline and solvate form A of cabergoline is also disclosed.

Forms of cabergoline

Provided are novel polymorphs and pseudopolymorphs of valacyclovir hydrochloride and pharmaceutical compositions containing these. Also provided are methods for making the novel polymorphs and pseudopolymorphs, which include valacyclovir hydrochloride monohydrate and valacyclovir hydrochloride dihydrate.

Crystalline forms of valacyclovir hydrochloride

The present invention relates to protected valacyclovir, N-tert-butoxycarbonyl-L-valine 2-[(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy] ethyl ester, and a method of making it. The present invention further relates to a method of making valacyclovir including the steps of coupling an amine protected valine selected from N-t-butoxycarbonyl valine and N-formyl valine with acyclovir using a coupling agent to form a protected valacyclovir, and deprotecting the protected valacyclovir to form valacyclovir or a pharmaceutically acceptable salt thereof. The present invention further relates to valacyclovir in pure form, a method of making pure valacyclovir, and to compositions containing pure valacyclovir.

Synthesis and purification of valacyclovir

Process and intermediates for production of cabergoline and related compounds

Process for making cyanomethyl ester precursors of flecainide

The present invention relates to a new process for the preparation of acetylcholinesterase inhibitors of formula (I) or a salt thereof, wherein: R is N-acyl-4-piperidyl; N-alkoxycarbonyl-4-piperidyl; N-alkyl-4-piperidyl; N-benzyl-4-piperidyl; N-(&ohgr;-aralkyl)-4-piperidyl; 4-pyridyl; R , R , R , and R are identical or different and each represents hydrogen, straight-chain or branched alkyl, aryl, hydroxy, alkoxy, aryloxy, benzyloxy, acyloxy, alkylthio, arylthio, benzylthio, acylamino, phthalimido or halogen; n is 1, 2 or 3; m is 1, 2, 3, 4, or 5. This process comprises cyclisation of a compound of formula (II) or salts thereof, wherein R , R , R , R and R , m and n are as defined above; R is selected from a derivatised or non-derivatised carboxyl, cyano, N-substituted aminocarbonyl groups or hydrogen; R is selected from a derivatised or non-derivatised carboxyl, cyano or N-substituted aminocarbonyl groups, optionally in the presence of acids and/or solvents. One of the most potent acetylcholinesterase inhibitors of the class of compounds prepared according to the present invention is donepezil.

Process and intermediates for production of donepezil and related compounds

Process for the preparation of flecainide

Growing community of inventors

Haifa, Israel

Boris Tishin